About

Age-related macular degeneration is a leading cause of vision loss in older adults, where an abnormal growth of leaky blood vessels under the retina causes rapid damage to central vision. Bevacizumab-vikg (LYTENAVA) is an antibody drug delivered as an eye injection that blocks VEGF-A, the protein signal that drives this harmful blood vessel growth. This mechanism aims to reduce the fluid leakage and bleeding, potentially slowing the vision loss from the wet form of the disease.